Research Article
Iron as the Key Modulator of Hepcidin Expression in Erythroid Antibody-Mediated Hypoplasia
Table 2
Hematological and biochemical data at the end of protocol (9 weeks).
| | Parameters | Groups | | Control | 50 IU rHuEPO | 200 IU rHuEPO |
| | EPO (mIU/mL) | 1.87 ± 0.25 | 1.65 ± 0.23 | 1.80 ± 0.21 | | Iron (µg/dL) | 183.63 ± 41.58 | 188.63 ± 35.27 |
255.14 ± 112.28a,b | | Ferritin (ng/dL) | 165.13 ± 19.19 | 168.50 ± 42.95 | 162.57 ± 39.81 | | Transferrin (mg/mL) | 97.75 ± 8.68 | 99.38 ± 6.59 | 96.14 ± 9.68 | | Glucose (mg/dL) | 160.88 ± 29.04 | 174.62 ± 20.21 | 187.71 ± 37.43 | | Creatinine (mg/dL) | 0.40 ± 0.05 | 0.37 ± 0.03 | 0.35 ± 0.06 | | Urea (mg/dL) | 45.10 ± 1.92 | 45.05 ± 3.56 | 42.74 ± 5.10 | | Uric acid (mg/dL) | 0.94 ± 0.46 | 0.70 ± 0.13 | 1.03 ± 0.52 | | Bilirubin (ng/mL) | 0.043 ± 0.016 | 0.054 ± 0.013 | 0.064 ± 0.014 | | IL-6 (pg/mL) | 138.10 ± 5.34 | 139.98 ± 6.12 | 130.16 ± 5.06a,b | | hsCRP (µg/mL) | 229.31 ± 24.55 | 237.49 ± 28.92 | 249.46 ± 33.49 | | IFN- (pg/mL) | 24.44 ± 23.07 | 21.45 ± 6.80 | 20.82 ± 10.13 | | TGF-β1 (ng/mL) | 80.21 ± 4.99 | 80.03 ± 17.22 | 78.10 ± 5.55 | | VEGF (pg/mL) | 5.36 ± 4.26 | 5.84 ± 3.85 | 6.04 ± 3.25 |
|
|
Results are expressed as mean ± SD. versus control; versus 50 IU rHuEPO. IL-6: interleukin-6; hsCRP: high-sensitive C-reactive protein; IFN-γ: interferon-γ; TGF-β: transforming growth factor beta1; VEGF: vascular endothelial growth factor.
|
